
Thrive Earlier Detection Stock
Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care.
Sign up today and learn more about Thrive Earlier Detection Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Thrive Earlier Detection Stock
Thrive Earlier Detection Corp. is a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives. Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences and Gamma3.
Funding History
May 2019 | $110M |
---|---|
July 2020 | $257M |
Management
Chief Commercial Officer
Matt Franklin
Founder
Kenneth Kinzler
CEO
David J. Daly
Founder
Nickolas Papadopoulos
Chief People Officer
Semi Trotto
Chief Financial Officer
Isaac Ro
Founder
Bert Vogelstein
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase